Our corporate department acted on behalf of Deciphex, an AI-enabled digital pathology platform, on a €31 million ($32.3 million) funding round from investors.

With over 70% of healthcare decisions requiring pathology investigation, Deciphex’s platforms, Diagnexia and Patholytix, enables pathologists to work up to 40% faster while maintaining diagnostic accuracy.

‍

Founder and Chief Executive, Donal O’Shea, commented, “This investment accelerates our mission to transform global pathology access. Our ergonomic, AI-enabled platform enhances diagnostic workflow and accuracy – allowing experts to clear backlogs faster without compromising quality”

‍

“By expanding this technology worldwide, we’re not just improving healthcare efficiency, we’re supporting both the pathologists who drive diagnoses and the patients who depend on them.”  

‍

Our Corporate, Banking & Employment teams advising Deciphex included Gavin Lawlor, Emma Kennelly, Mark Roberts, Michael Hanley, Caoimhe Heery, Danny Heffernan, Kate Duffy and Daniel Hackett.

‍

No items found.